Specialty Pharmacy

Investigators believe that urine sampling can be used to diagnose and treat bladder cancer.

Top news of the day from across the health care landscape.

In an ideal world, how would you hypothesize that technology might be able to solve all of your problems?

Doug Long, MBA, vice president of industry relations at IQVIA, discusses how vertical integration will affect health care delivery.

Galcanezumab-gnlm (Emgality, Eli Lilly) may be an effective option for patients who failed previous migraine preventive treatments.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The phase 3 IMvigor130 study is the first to assess a cancer immunotherapy combination in previously untreated advanced bladder cancer.

Top news of the day from across the health care landscape.

The conference will take place in conjunction with the 7th National Association of Specialty Pharmacy Annual Meeting & Expo.

A regimen of afatinib as a first-line treatment followed by osimertinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer was found to significantly improve overall survival.

Identifying gene-pair relationships may help scientists understand why mutations in certain genes lead to cancer in certain tissues.

Top news of the day from across the health care landscape.

Officials with the FDA are assessing data accuracy issues related to Zolgensma, but have no major concerns about the spinal muscular atrophy treatment remaining on the market.

Effective patient-provider communication is critical to the healing process and it begins the moment the patient makes contact with the staff and continues even after the patient fills his prescription at the pharmacy.

Research could lead to the development of new cancer treatments to stop tumor growth.

Top news of the day from across the health care landscape.

Over the last 5 years, more than 4000 FDA-regulated clinical trials were initiated worldwide for rare disease treatments.

Pexidartinib (Turalio, Daiichi Sankyo) is indicated for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Top news of the day from across the health care landscape.

The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigorous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.

With rapid growth, health system specialty pharmacies are more than likely to run into several operational pain points.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Pembrolizumab (Keytruda, Merck) plus chemotherapy met the primary endpoint of pathological complete response in patients with triple-negative breast cancer in a phase 3 study.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The findings represent the first positive phase 2b study of a personalized cancer vaccine in patients with high-risk melanoma.